CRISPR Therapeutics AG
CRISPR Therapeutics AG
IND Enabling
Phase I
Phase II
Phase III
IND Enabling
Phase I
Phase II
Phase III
IND Enabling
Phase I
Phase II
Phase III
IND Enabling
Phase I
Phase II
Phase III
IND Enabling
Phase I
Phase II
Phase III
Relapsed or Refractory B-Cell Malignancies, Non-Hodgkin lymphoma, NHL, (2018-003916-38)
Sponsors:
CRISPR Therapeutics AG
Sponsors:
CRISPR Therapeutics AG
IND Enabling
Phase I
Phase II
Phase III
IND Enabling
Phase I
Phase II
Phase III
IND Enabling
Phase I
Phase II
Phase III